Delving into the Latest Updates on TY-2699a with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TY 2699A, TY 2699a, TY2699a

Target

CDK7

Mechanism

CDK7 inhibitors(Cyclin-dependent kinase 7 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases

Active Indication

Locally Advanced Malignant Solid NeoplasmSmall Cell Lung CancerTriple Negative Breast Cancer+ [2]

Inactive Indication-

Originator Organization

TYK Medicines, Inc.Startup

Active Organization

TYK Medicines, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of TY-2699a capsules at different doses in patients with advanced/metastatic solid tumors and determine the MTD and RP2D. Secondary objective: To evaluate the pharmacokinetic characteristics and preliminary antitumor activity of TY-2699a in patients with advanced/metastatic solid tumors

Start Date14 Aug 2023

Sponsor / Collaborator

TYK Medicines, Inc.Startup

100 Clinical Results associated with TY-2699a

Login to view more data

100 Translational Medicine associated with TY-2699a

Login to view more data

100 Patents (Medical) associated with TY-2699a

Login to view more data

100 Deals associated with TY-2699a

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Malignant Solid Neoplasm	Phase 1	CN	TYK Medicines, Inc.Startup	17 Aug 2023
Small Cell Lung Cancer	Phase 1	CN	TYK Medicines, Inc.Startup	-
Triple Negative Breast Cancer	Phase 1	CN	TYK Medicines, Inc.Startup	-
Metastatic Solid Tumor	IND Approval	CN	TYK Medicines, Inc.Startup	08 Feb 2025
Solid tumor	IND Approval	US	TYK Medicines, Inc.Startup	15 Feb 2023